Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

– Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022 – – Transaction, upon closing, will solidify balance sheet and the Company intends to pay…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.